Piper Sandler raised the firm’s price target on PacBio (PACB) to $1.50 from $1.25 following quarterly results. The firm keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Pacific Biosciences: Strong Q2 Performance and Strategic Initiatives Drive Buy Rating
- PacBio price target raised to $1.70 from $1.50 at Bernstein
- PacBio Reports Revenue Growth and Strategic Advances
- Positive Long-Term Outlook for Pacific Biosciences Amid Strong Q2 Performance and Strategic Innovations
- PacBio reports Q2 EPS (13c), consensus (17c)